The US pharma said results of the latest phase 3 trial showed that REGEN-COV (casirivimab+imdevimab) significantly reduced progression to symptomatic COVID-19 disease in uninfected individuals.

It’s a dictum that has stood him well during his 30-year career as a top executive at Regeneron Pharmaceuticals, which received widespread publicity late last year after former President Donald Trump ...

REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST ...

The Business Research Company's Regen-cov And Ronapreve Global market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to ...